| Property | Value |
|---|
|
?:abstract
|
-
For the last decade, intravenous (i.v.) iron to treat anaemia before surgery has been a key pillar of patient blood management. Recognising the associations between pre-operative anaemia and poor postoperative outcome, it was postulated that treatment of anaemia with iron (particularly in the setting of iron deficiency) would reduce the requirement for allogeneic red blood cell transfusion and improve postoperative outcomes. Accordingly, these recommendations were incorporated into national guidelines, despite a tacit acknowledgement that the overall quality of evidence was poor.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
The end of the beginning: pre-operative intravenous iron and the PREVENTT trial.
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}